Somerville, MA, United States of America

Sara Jean Buhrlage

This inventor holds 24 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Cancer Therapeutics. Top assignees: Dana-Farber-Cancer Institute Inc., Harvard College, The General Hospital Corporation. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sara Jean Buhrlage. Retrieved from https://idiyas.com/inventor/sara-jean-buhrlage

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 8)

% Patents Active = 95.8

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 7 (Patent Applications = 21)

Average Co-Inventor Count = 4.6

ph-index = 5

Forward Citations = 42(Granted Patents)

Company Filing History:

23 out of 1,268

Dana-Farber-Cancer Institute Inc.

The General Hospital Corporation

patents

4. 1 out of 27

Centre Hospitalier Universitaire Vaudois

patents

5. 1 out of 5

Fondazione Centro San Raffaele

patents

6. 1 out of 8,586

Massachusetts Institute of Technology

patents

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

USP7 Inhibitors

HCK Targeting

Thiazolyl Compounds

Multiple Myeloma

Lymphoplasmacytic Lymphoma

Hematologic Malignancies

Small Molecule Inhibitors

Cancer Treatment

Proliferative Diseases

Interleukin-1 Inhibitors

Biomarkers

Sonic Hedgehog Modulators

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12692250 - NOVEL USP7 INHIBITORS FOR TREATING MULTIPLE MYELOMA (2026-07-28),

2. 12679842 - HCK as a therapeutic target in MYD88 mutated diseases (2026-07-14),

3. 12668571 - Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28 (2026-06-30),

4. 12655155 - Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28 (2026-06-16),

5. 12564591 - HCK as a therapeutic target in MYD88 mutated diseases (2026-03-03),

6. 12503453 - USP7 INHIBITION (2025-12-23),

7. RE50030 - Methods to treat lymphoplasmacytic lymphoma (2024-07-02),

8. 11465983 - USP7 inhibitors for treating multiple myeloma (2022-10-11),

9. 11447467 - Compounds for the degradation of STK4 and treatment of hematologic malignancies (2022-09-20),

10. 11136409 - Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators (2021-10-05),

11. 11136291 - Antifungal compounds and uses thereof (2021-10-05),

12. 10975055 - Inhibitors of interleukin-1 receptor-associated kinases and uses thereof (2021-04-13),

13. 10844077 - Thiazolyl-containing compounds for treating proliferative diseases (2020-11-24),

14. 10710978 - STK4 inhibitors for treatment of hematologic malignancies (2020-07-14),

15. 10633348 - Methods to treat lymphoplasmacytic lymphoma (2020-04-28),

Title: **Innovative Contributions of Inventor Sara Jean Buhrlage**

Introduction

Sara Jean Buhrlage, an accomplished inventor based in Somerville, MA, has made significant strides in the field of oncology. With a total of 18 patents to her name, she has demonstrated an exceptional ability to innovate and contribute to cancer treatment. Her work focuses primarily on developing methods for treating lymphoplasmacytic lymphoma and other related B cell neoplasms.

Latest Patents

Among her latest patents, one notable invention is centered around methods to treat lymphoplasmacytic lymphoma. This invention provides compounds represented by various formulas (A, I-11, II, and V), specifically targeting Waldenström's macroglobulinemia and other B cell neoplasms. The methods involve administering effective amounts of these compounds to subjects in need, also exploring combinations with inhibitors of Bruton's tyrosine kinase (BTK) and other associated kinases.

Another significant patent involves USP7 inhibitors for treating multiple myeloma. This disclosure highlights the inhibitors' potential in treating cancers and other diseases mediated by USP7, offering promising avenues for future cancer therapies.

Career Highlights

Sara Jean Buhrlage has had a distinguished career, gaining experience at prominent institutions such as the Dana-Farber Cancer Institute and Harvard College. Her innovative research and dedication to cancer treatment have solidified her reputation within the scientific community.

Collaborations

Throughout her career, Sara has collaborated with notable professionals, including Nathanael Schiander Gray and Steven P Treon. These collaborations have provided her with a platform to expand her research and contribute to groundbreaking discoveries in cancer therapeutics.

Conclusion

Sara Jean Buhrlage’s contributions to the field of oncology through her numerous patents reflect her dedication to innovating cancer treatments. Her work continues to impact the lives of those affected by B cell neoplasms, showcasing her as a leading figure among inventors in the medical research sector.

Profile summary based on public USPTO records.